EQL Pharma

55,50 SEK

-2,29 %

Mindre end 1K følgere

EQL

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Dividend

Investorkonsensus

-2,29 %

-13,69 %

-3,98 %

+9,47 %

-32,48 %

-32,48 %

+46,05 %

+48,00 %

+932,61 %

EQL Pharma operates in the pharmaceutical industry and focuses on the development, manufacturing and distribution of generic medicines. The company's products are aimed at healthcare institutions and patients who need cost-effective treatment options. The business is global with a primary presence in Europe, North America and Asia. EQL Pharma was founded in 2006 and is headquartered in Lund, Sweden.

Markedsværdi

1,64 mia. SEK

Aktieomsætning

1,1 mio. SEK

Omsætning

373,52 mio.

EBIT %

18,04 %

P/E

37,5

Udbytteafkast, %

-

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

8.5

2026

Årsrapport '26

Alle

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Selskabsmeddelelse12.2.2026, 12.22

EQL Pharma: Nomination committee for the 2026 Annual General Meeting

Pressemeddelelse4.2.2026, 08.19

DNB Carnegie Access: EQL Pharma: Solid Q3 with branded-driven EBIT beat – worst behind it

Pressemeddelelse3.2.2026, 13.25

DNB Carnegie Access: EQL Pharma: Q3 2025/26 initial: Beat driven by strong branded sales

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse3.2.2026, 13.15

Bulletin from the extraordinary general meeting in EQL Pharma AB on 3 February 2026

Selskabsmeddelelse3.2.2026, 11.30

EQL Pharma: Interim Report April - December 2025

Pressemeddelelse27.1.2026, 06.15

DNB Carnegie Access: EQL Pharma: From reset to recovery – Q3 2025/26 preview

Pressemeddelelse15.1.2026, 10.40

Invitation to presentation in connection with EQL Pharma's interim report, third quarter, 2025/26

Selskabsmeddelelse7.1.2026, 12.29

Notice of extraordinary general meeting in EQL Pharma AB

Selskabsmeddelelse4.12.2025, 09.00

EQL Pharma recruits Anne D Jensen as new Chief Sales Officer (CSO) and Carl Lindgren leaves his position as Chief Business Development Officer (CBDO)

Selskabsmeddelelse3.12.2025, 13.36

EQL Pharma recruits Allan Sylvest Aasberg as new Chief Financial Officer (CFO)

Selskabsmeddelelse17.11.2025, 12.57

EQL Pharma AB (publ) publishes prospectus and applies for admission to trading of bonds on the corporate bond list of Nasdaq Stockholm

Pressemeddelelse14.11.2025, 12.49

EQL Pharma: Methenamine Hippurate (branded as Cystohipp©) have gained marketing approval in Germany

Pressemeddelelse6.11.2025, 07.08

DNB Carnegie Access: EQL Pharma: Branded sales and restocking to drive recovery

Pressemeddelelse5.11.2025, 07.41

DNB Carnegie Access: EQL Pharma: Weak set of numbers, as expected – Q2 initial take

Selskabsmeddelelse5.11.2025, 06.00

EQL Pharma: Interim Report April - September 2025

Pressemeddelelse31.10.2025, 06.43

DNB Carnegie Access: EQL Pharma: Temporary softness in Q2 as visibility recovers – Q2 preview

Pressemeddelelse22.10.2025, 09.27

Invitation to presentation in connection with EQL Pharma's interim report, second quarter, 2025/26

Selskabsmeddelelse6.10.2025, 13.08

EQL Pharma in process of recruiting new Chief Commercial Officer (CCO)

Selskabsmeddelelse30.9.2025, 08.00

Change in number of shares and votes in EQL Pharma AB

Pressemeddelelse23.9.2025, 12.59

EQL Pharma: Mellozzan® (melatonin) launched in the UK

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.